Litigation Details for Aetna Inc. v. AstraZeneca LP (N.D. Cal. 2023)
✉ Email this page to a colleague
Aetna Inc. v. AstraZeneca LP (N.D. Cal. 2023)
| Docket | ⤷ Try a Trial | Date Filed | 2023-02-20 |
| Court | District Court, N.D. California | Date Terminated | 2023-02-22 |
| Cause | 28:1332 Diversity-(Citizenship) | Assigned To | Joseph Spero |
| Jury Demand | None | Referred To | |
| Patents | 6,923,984 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Aetna Inc. v. AstraZeneca LP
The small molecule drug covered by the patent cited in this case is ⤷ Try a Trial .
Details for Aetna Inc. v. AstraZeneca LP (N.D. Cal. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-02-20 | 1 | described in U.S. Pat. No. 6,923,984, incorporated herein by 7 reference…recently 4 issued U.S. Patent No. 5,948,437 (the “’437 Patent”), a follow-on patent, which purportedly ….8 To obtain its patent, Handa had disclosed AstraZeneca’s ’288 Patent and ’437 Patent as 1 prior…the owner of U.S. Patent No. 4,879,288 (“the 9 ’288 Patent”). The ’288 Patent issued on November… AstraZeneca has held U.S. Patent No. 4,879,288 (the “’288 Patent”), covering the 25 chemical | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
